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In this clinical trial, we investigated if biochemical bone turnover markers (BTM) changed according to the progression of bone
healing induced by autologous expanded MSC combined with a biphasic calcium phosphate in patients with delayed union or
nonunion of long bone fractures. Bone formation markers, bone resorption markers, and osteoclast regulatory proteins were
measured by enzymatic immunoassay before surgery and after 6, 12, and 24 weeks. A satisfactory bone healing was obtained in
23 out of 24 patients. Nine subjects reached a good consolidation already at 12 weeks, and they were considered as the “early
consolidation” group. We found that bone-speciﬁc alkaline phosphatase (BAP), C-terminal propeptide of type I procollagen
(PICP), and beta crosslaps collagen (CTX) changed after the regenerative treatment, BAP and CTX correlated to the imaging
results collected at 12 and 24 weeks, and BAP variation along the healing course diﬀered in patients who had an “early
consolidation.” A remarkable decrease in BAP and PICP was observed at all time points in a single patient who experienced a
treatment failure, but the predictive value of BTM changes cannot be determined. Our ﬁndings suggest that BTM are promising
tools for monitoring cell therapy eﬃcacy in bone nonunions, but studies with larger patient numbers are required to conﬁrm
these preliminary results.
1. Introduction
Normal fracture healing in adults occurs through intramem-
branous or endochondral bone formation, depending on the
primary stability of the fracture site: if stability is maintained
through a rigid ﬁxation and a perfect reduction, the healing
may proceed through an intramembranous mechanism with
limited cartilaginous callus formation [1]. Bone healing after
fracture is a complex process ﬁnely tuned where several types
of cells, factors, and molecules cooperate locally to restore
tissue continuity and function. The “biology” of bone repair,
that is, the progression of biochemical and molecular
signals during healing of bone, has been described by sev-
eral authors [2, 3]. The ability to assess cells and molecules
involved in bone turnover during fracture healing would
aid in monitoring the reparative process and in predicting
the treatment outcome. Despite the ability of bone for self-
healing, quite a high incidence of delayed and nonunion of
long bone fractures is recorded, also due to concomitant
factors such as diabetes, osteoporosis, metabolic diseases,
infection, and smoking [4]. Actually, the healing process
was shown to slow down with advancing age, possibly
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due to a lower number of mesenchymal stem cells, or a
decrease in their mitogenic potential, or to a poor response
to therapeutic interventions [5].
Conventional treatments to heal nonunions include
autologous bone graft, combined with internal/external ﬁxa-
tion, synthetic bone substitutes, including resorbable calcium
phosphates, and distraction osteogenesis, too. Adjuvants to
these treatments, such as bone morphogenetic proteins,
platelet-rich plasma, and low-intensity pulsed ultrasound,
have been employed to promote local biology [6, 7].
Cell- and/or growth factor-based strategies in bone tissue
engineering and regenerative medicine are increasingly
applied as an alternative to standard surgery, with often sub-
stantial beneﬁt for patients [8, 9]. The eﬃcacy ofMSC to boost
local healing has been proved in diﬀerent clinical settings, and
positive results have been reported using a concentrated bone
marrow (BM) aspirate [10, 11], even if more beneﬁts may be
obtained from expandedmesenchymal cells [12]. Both strate-
gies aim at enhancing the proportion of active mesenchymal
cells, since it is known that the skeletal progenitors in the
BM aspirate are rather few (1 in 108 cells), with their number
and quality steadily declining with age [13], while their num-
ber does matter in the healing process of bone defects [14].
The paracrine activity of MSC, with a release of cyto-
kines, chemokines, and other active molecules, has been rec-
ognized as an eﬀector of tissue repair since 20 years and
recently described as a major mechanism in bone regenera-
tion [15, 16]. However, the complex network of molecules
and factors acting at the healing site prevents an easy identi-
ﬁcation, and, more importantly, these measurements are
invasive and cannot be used in humans [17].
Indeed, the eﬃcacy of the regenerative therapies, that is,
bone formation, is currently assessed mostly by X-ray and
microcomputed tomography imaging, as well as clinical
examination, while other indices, possibly quantitative mea-
surements, are required. The identiﬁcation of biological
markers to help in monitoring the treatment eﬃcacy might
facilitate the patient management. By serology, the level of
molecules produced at the healing site, to enter circulation
afterwards, may be measured and hopefully provide a biolog-
ical monitoring of the fracture consolidation. However, no
studies on this issue are available so far.
In the search for “signals” of MSC regenerating ability, we
evaluated prospectively a cohort of patients aﬀected by long
bone delayed union or nonunion enrolled in a “Seventh
Framework Program” (FP7) European project and treated
with a regenerative therapy with expanded autologous MSC
plus a synthetic bone substitute. We analyzed changes of a
panel of serum bone turnover markers (BTM), commonly
used for monitoring the remodelling process [18–20], which
were measured at ﬁxed time points according to the schedule
of the clinical protocol. We aimed to search for relation, if
any, with the treatment outcome, that is, fracture consolida-
tion by clinical and radiological assessment up to one year.
2. Patients and Methods
2.1. Study Participants and Treatment. In this study, patients
aﬀected by delayed union or nonunion of the long bones,
aged 18–65 years, were recruited in a prospective, controlled,
multicentric, phase I/IIa, and interventional clinical trial
entitled “Evaluation of Eﬃcacy and Safety of Autologous
MSCs Combined to Biomaterials to Enhance Bone Healing
(OrthoCT1)” (ClinicalTrials.gov identiﬁer: NCT01842477).
The inclusion criteria were the following: age 18 to 65,
both sexes; delayed union or nonunion at least 3 months
from a traumatic, isolated, closed or open, and diaphyseal
or metaphysodiaphyseal fracture of long bone. The exclusion
criteria were the following: pregnant or breast-feeding
women, women who are of childbearing age and not practic-
ing adequate birth control, participation in another thera-
peutic trial in the previous 3 months; delayed union or
nonunion related to iatrogenic causes; segmental bone loss
requiring speciﬁc therapy (bone transport, large structural
allograft, megaprosthesis, etc.); vascular or neural injury;
other fractures causing interference with weight-bearing;
infection of skin, soft tissue, bone, or any remote infection,
that is, dental, pulmonary, and gynecological; visceral inju-
ries of diseases interfering with callus formation (cranio-
encephalic trauma, etc.); history of bone harvesting on
iliac crest contraindicating bone marrow aspiration; corti-
coid or immunosuppressive therapy more than one week
in three months prior to study inclusion; history of prior
or concurrent diagnosis of HIV, hepatitis B, or hepatitis
C infection; history of neoplasia or current neoplasia in
any organ; insulin-dependent diabetes; obesity (BMI > 30);
autoimmune inﬂammatory disease; and current treatment
by bisphosphonate or stopped in the three months prior
to inclusion.
The regenerative approach consisted in a minimally
invasive administration of autologous bone marrow cells
expanded in Good Manufacturing Practice (GMP) facilities
(Fondazione IRCCS Ca’ Granda Ospedale Maggiore Poli-
clinico, Milano, Italy; Établissement Français du Sang
(EFS), Toulouse, France; EFS, Creteil, France; Transfusion
Medicine Institute of Ulm, Germany; and Cell Production
Unit at Hospital Puerta de Hierro-Majadahonda, Madrid,
Spain) and surgically implanted with synthetic biphasic
calcium phosphate, that is, 20% hydroxyapatite (HA) and
80% beta tricalcium phosphate (β-TCP), in 1-2mm
granules (MBCP+, Biomatlante SA, Vigneux-de-Bretagne,
France) (Figures 1(a) and 1(b)).
Bone marrow harvesting was performed in an operating
room under anesthesia, from the posterior iliac crest, with a
trocar by cutaneous puncture. Bone marrow was aspirated
by fractions of 2–4ml in 20ml heparin-preﬁlled syringes,
then transferred to the GMP facility, following standard pro-
cedures for the transport and cell expansion previously deter-
mined [21, 22] (Figure 1(c)).
A standard procedure was applied during the implanta-
tion surgery. In the operating room, 200× 106-expanded
MSC were mixed with 10 cc of MBCP+ granules for 60
minutes, then implanted in the bone defect by using two
5 cc syringes (Figure 1(d)). Preclinical studies showed that
less than 5% BM-MSC remained in the supernatant or
attached to the container after 60 minutes and that cells on
the calcium phosphate granules were capable of forming
bone [23].
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The progression of bone healing was evaluated at 6, 12,
and 24 weeks after implantation (Figure 2), by clinical and
radiological assessment, including visual assessment score
(VAS) for pain, digital X-ray (XR), and helicoidal computed
tomography (CT) imaging, functional recovery (full weight-
bearing gait), and related local complications. Main outcome
measure was the time to consolidation, that is, 3 out of 4 or 2
out of 3 cortices on lateral and frontal views, with imaging
conﬁrmed bone bridging [24].
2.2. Blood Collection and Sample Storage. Each centre partic-
ipating to the clinical trial collected blood samples as sched-
uled, that is, at the time of bone marrow harvesting from
the iliac crest (visit 1) and, postoperatively, that is at 6 (visit
4), 12 (visit 5), and 24 weeks (visit 6) after surgery for autol-
ogous MSC/MBCP+ insertion at the fracture site (Figure 2).
A fasting morning blood collection was performed, whenever
possible. The blood samples were centrifuged within 2 hours
from collection, at 1000 g for 15 minutes at room tempera-
ture. The serum was transferred into 12 cryotubes (0.5ml
of serum per cryotube) tagged with a small label showing
the project name, acronym of the clinical centre, visit num-
ber, date, and patient’s inclusion number. The cryotubes
were frozen at −20 or −80 degrees Celsius within 4 hours
from centrifugation. Later, six frozen cryotubes were sent to
the Orthopedic Pathophysiology and Regenerative Medicine
Unit of Rizzoli Orthopedic Institute, where all the immu-
noenzymatic assays were performed.
2.3. Immunoenzymatic Assay of BTM. The laboratory per-
sonnel performing the immunoenzymatic assay was unaware
of the source of the samples, which were marked with numer-
ical codes. The BTM circulating levels were measured using
commercially available reagents based on a sandwich enzyme
immunoassay technique, following the manufacturer’s pro-
tocols, with each sample tested in duplicate. Table 1 shows
the list of the BTM selected with a brief description of the
source of reagents and the technical notes.
2.4. Calculations and Statistical Analysis. Statistical analysis
was performed using the StatView 5.0.1 software (SAS Insti-
tute Inc., Cary, NC). Data have been expressed as mean
± standard error of the mean of analyte concentration at
the diﬀerent time points and as changes from the baseline
value measured at bone marrow harvest. The changes over
time have been calculated as follows:
At visit 1 (BM harvesting): 1 − [BTM visit 1/BTM
visit 1] = 0 (baseline).
At visit 4: 1 − [BTM visit 4/BTM visit 1].
At visit 5: 1 − [BTM visit 5/BTM visit 1].
At visit 6: 1 − [BTM visit 6/BTM visit 1].
A nonparametric paired analysis of the data (Wilcoxon
signed-rank test) was applied patient by patient to detect
changes of BTM over time, from visit 1 to visit 6. The
Mann–Whitney U test was used to highlight signiﬁcant
diﬀerences between two independent variables. P values
< 0.05 were considered as statistically signiﬁcant.
3. Results
3.1. Clinical Outcome. Blood samples were collected from
twenty-six subjects admitted to the clinical trial, whose
demographic and clinical characteristics are shown in
Table 2. Two patient dropped out after visit 1 and visit 5.
(a)
(b)
(c) (d)
Figure 1: (a) Syringe containing the 1-2mm MBCP+ granules (5ml) and (b) scanning electron microscopy picture of the material
macroporosity (×30 magniﬁcation). (c) Monolayer of bone marrow-derived mesenchymal stromal cells after expansion (alkaline
phosphatase cytochemical staining, ×4 magniﬁcation). (d) The MSC/MBCP+ mixture is injected into the nonunion fracture site.
Trial
period Screening Pretreatment Treatment Follow‐up
Visit 0 1 2 3 4 5 6 7
Screening
Bone
marrow
harvesting
Day before
implantation
surgery
Implantation
surgery
6 weeks
after
surgery
12 weeks
after
surgery
24 weeks
after
surgery
52 weeks
after
surgery
Days ‒30‒7 1 20 21 59‒73 101‒115 185‒199 381‒395
Figure 2: Time course of the OrthoCT1 protocol with the time points of blood collection in green.
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A satisfactory bone healing was obtained in 23 out of the
24 patients, while one patient without a complete healing was
scored as a “failure” at visit 6. Nine subjects reached a good
consolidation already at visit 5, and they were considered as
the “early consolidation” group.
Representative radiological views are given in Figure 3.
3.2. Signiﬁcant Changes in BTM Levels Are Observed after the
Regenerative Treatment. Circulating levels of BTM have been
measured in all patients at visit 1, but to highlight the changes
over time, we considered only the twenty-four patients with
prospective evaluation. At each time point, BTM values were
not normally distributed, and a high variability was observed
for all markers. Except for PICP and OC, either intact or
cleaved, at visit 1, BTM levels tended to be higher than refer-
ence values of healthy individuals (Table 1). To verify if
signiﬁcant changes of BTM were induced by implantation
of expanded MSC/MBCP+, a patient-by-patient comparison
was made (Table 3). After 6 and 12 weeks from surgery, a sig-
niﬁcant increase in BAP concentration was observed, while
CTX and int-OC decreased. Also N-mid OC and PICP
decreased after 6 weeks, while a signiﬁcant change of RANKL
was detected after 12 weeks. At 24 weeks, concentrations of
all BTM were similar to those observed before treatment.
3.3. Some BTM Correlate with Radiological Findings at the
Same Time Point. The BTM changes have been calculated
for each patient and expressed as previously described, that
is, as a ratio between serum concentrations measured at each
time point and at baseline (visit 1).
A relationship between BTM changes at 12 and 24 weeks
and the healing status by imaging at the same time points was
searched. CTX variation was over the baseline level in
patients who exhibited a bone bridging at 12 weeks
(Figure 4(a)), while decreased in subjects with incomplete
consolidation. At 24 weeks, the BAP increase found in the
most part of patients was less pronounced in cases with a
complete healing (Figure 4(b)).
3.4. BTM in Patients with “Early Consolidation” Change with
a Diﬀerent Time Course. The relationship between BTM
changes and primary outcome, that is, fracture consolidation
by clinical and radiological assessment up to one year, is
shown in Figure 5. At this ﬁnal time point, 23 out of 24
patients showed a positive outcome, with 8 patients scored
as “early consolidation” and 15 patients with positive out-
come within one year.
In patients with an “early consolidation,” the BAP level
was signiﬁcantly increased already at 6 weeks, to further
increase at 12 weeks, while in patients who consolidated
within one year, a statistically signiﬁcant BAP increase was
observed afterwards, that is, at 12 and 24 weeks.
PICP, int-OC, and N-mid OC were signiﬁcantly
decreased at 6 weeks in patients healed after 24 weeks, to
increase afterward, with changes not signiﬁcantly diﬀerent
from baseline values. OPG was increasing over time, but no
signiﬁcant changes were detected, while RANKL was reduced
at 12 weeks in patients who consolidated within one year and
at 24 weeks in patients with “early consolidation.” However,
no signiﬁcant diﬀerences were found between the group of 8
patients who healed within 12 weeks (early consolidation)
and the 15 subjects who healed later. Figure 5 also shows
the variations versus baseline observed in the single patient
who experienced a treatment failure. This patient had a
remarkable decrease of BAP and PICP at all time points,
while OPG dropped after 6 weeks and RANKL increased dra-
matically up to 12 weeks.
4. Discussion
As recently reported, 5–15% of bone fractures end in
impaired bone healing, with additional surgery requirements,
even if the nonunion incidence varies signiﬁcantly depending
on the anatomic site and the clinical criteria used to deﬁne
nonunion. High-energy trauma, inappropriate fracture ﬁxa-
tion, large bone loss, low blood supply, and infection have
been reported as main reasons for nonunion [25, 26]. The
rather high incidence of fracture-delayed unions or non-
unions has opened the way to “orthobiologics,” including
mesenchymal stromal cells, as well as growth factors or ana-
bolic drugs to accelerate consolidation and prevent or treat
delayed unions or nonunions [27, 28].
Following any MSC-based therapeutic intervention on
bone, the amount of tissue that is regenerated cannot be
Table 2: Demographic and clinical characteristics of patient cohort.
Number of subjects evaluated at Rizzoli Orthopedic
Institute
N = 26
Age
Mean± standard deviation 39.6± 14
Median 41.5
Range 19–65
Gender
Males N = 15
Females N = 11
Site of lesion
Femur N = 11
Tibia N = 9
Tibia & Fibula N = 2
Humerus N = 3
Not recorded N = 1
Surgery and Osteosynthesisa N = 25
Nail N = 15
Plate N = 9
External ﬁxator N = 1
Patients with complete blood sample collection
(4 time points)
N = 23
Patients prospectively evaluated (at least 2 time points) N = 24
Final outcome
Consolidation N = 23
Failure N = 1
aOne patient was recruited but not operated on.
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reliably predicted. As remarked by Ginis et al., radiological
images may overestimate the extent of bone formation dur-
ing regeneration, but the identiﬁcation of “true” new bone
at the site of regeneration, as obtained by histology and histo-
morphometry in “in vivo” models, is not feasible in humans
[29]. Biomarkers of the activity of bone remodeling may pro-
vide additional information beyond radiographic assess-
ments, but to date, a biological factor useful to the clinical
monitoring of bone healing has not been identiﬁed [30].
Bone turnover markers are routinely used in the diagnosis
or treatment monitoring of several bone diseases, such as
osteoporosis or Paget’s disease, and shown to correlate with
clinical ﬁndings and bone imaging [31]. In addition, they
have been studied also for monitoring the healing process
of fractures and for the early detection of fracture-healing
disturbance [32–34].
In this study, we hypothesized that circulating BTM
could reﬂect the healing process induced by the regenerative
boost of expanded MSC combined with calcium phosphate
and that changes of BTM over time could predict the treat-
ment outcome, that is, the consolidation of the bone lesion.
In order to accomplish our goal, a panel of seven markers
belonging to the three main categories of BTM, that is,
markers of bone formation (BAP, PICP, intact-OC, and
N-mid OC), bone resorption markers (CTX, intact-OC,
and N-mid OC), and osteoclast regulatory proteins (OPG
and RANKL), was selected [18–20, 32–35].
BAP is expressed early during the diﬀerentiation of
mesenchymal progenitors into osteoblasts, and its circulating
levels seem to be directly related to the number and diﬀerenti-
ation state of osteoblasts [32]. PICP directly reﬂects the forma-
tion rate of type I collagen, and often, after an initial decrease
in PICP levels, the turnover of type I collagen in fractured
patients shows a gradual rise over time [36]. To complete the
picture of the matrix synthesis, OC, a noncollagenous protein
released by diﬀerentiated osteoblasts, was measured. OC is
incorporated into the organic bone matrix, and only a small
fraction is circulating. Even though it is widely accepted as a
marker of osteoblastic activity [37], during bone resorption,
the OC entrapped in the mineralized matrix is released so that
serum concentration also reﬂects the osteolytic process; hence,
OC is considered amarker of bone turnover, rather than a spe-
ciﬁc marker of bone formation. Intact OC (amino acids 1–49)
is unstable due to protease promoting the cleavage between
amino acids 43 and 44, while the N-mid fragment (amino
acids 1–43) is considerably more stable [38].
OPG and RANKL are regarded asmain regulators of oste-
oclast diﬀerentiation and function. The pro-osteoclastogenic
factor RANKL is released by mature osteoblasts in order to
activate the resorption and to initiate the remodeling cycle
in basic multicellular units. Bone-forming cells produce also
OPG, which acts as a decoy receptor and modulates RANKL
activity, in order to maintain a balance between bone forma-
tion and bone resorption [39].
During the callus remodeling, an increase of markers of
bone resorption is expected [33]. As a marker, we selected
CTX that derives from the digestion of type 1 collagen medi-
ated by cathepsin K produced by osteoclasts [32, 40].
(a) (b) (c) (d)
Figure 3: Representative radiological images (lateral view) of a male, 19 years, with irregular complex tibia fracture (1/3 distal diaphysis) not
healed after 12 months from trauma; (a) visit 1: pretreatment, day before surgery; (b) visit 3: after implantation surgery; (c) visit 6 at 24 weeks:
callus with the same density as cortical; (d) visit 7 at 52 weeks: consolidation.
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All the markers, but CTX, are directly or indirectly
related to the osteoblast diﬀerentiation, and therefore, they
could be useful to follow in vivo the bone regeneration pro-
moted by cell therapies based on mesenchymal stromal cells.
According to the ﬁnal result of the clinical trial, only one
of the recruited patients did not reach a stable consolidation
within one year from the regenerative treatment. As a conse-
quence, no chance to calculate the predictive value of BTM
was given. However, our data allowed to verify if BTM levels
(i) changed after the regenerative therapy based on ex vivo
expanded MSC, (ii) correlated to the imaging results at visit
5 and visit 6, and (iii) diﬀered in patients who had an “early
consolidation.”
Actually, BTM changed over time, and all variations, but
OPG, were statistically signiﬁcant at one or more time points,
with a peak at 6 weeks from surgery when 5 out of 7 markers
showed signiﬁcant changes. An increase in BAP concentra-
tion was observed, while PICP, CTX, and both OC tended
to decrease. This picture was maintained at the midpoint
(12 weeks) with the addition of a signiﬁcant decrease in
RANKL levels, but at 24 weeks, all BTM returned to values
observed at baseline.
We expected that our results could reﬂect the kinetics of
BTM during the fracture healing, even if literature data on
this topic are quite controversial. The BAP increase, from 4
weeks after fracture up to one year, is conﬁrmed by a number
of studies [33, 41–44]. However, other BTM such as CTX,
PICP, and OC, have been shown to increase following an ini-
tial fall after fracture [32, 33], but we did not ﬁnd this result in
our case series. Few studies have analyzed the serum levels of
RANKL and OPG during the fracture healing process, and a
high variability of results was found [45–47]. Therefore, our
ﬁndings suggest that bone repair steps following the physio-
logical fracture healing or a regenerative treatment diﬀer to
some extent.
Then, it was veriﬁed whether there was a relationship
between BTM changes at 12 and 24 weeks and the healing
status evaluated by XR or CT at the same time points, and
we found that CTX and BAP correlated with the imaging
results. CTX variation was over the baseline value in patients
who were already healed at 12 weeks, while a negative value
was recorded in patients with an incomplete consolidation.
At 24 weeks, a BAP increase was found in the most part of
patients, but the rise was less pronounced when the consoli-
dation was reached. These ﬁndings reﬂect what is expected at
the end of the bone healing process, when the osteogenic
phase is progressively silenced and the remodeling phase pre-
vails [34, 48].
Finally, we try to understand if the overall BTM variation
along the healing course was diﬀerent in patients who had an
Table 3: Circulating BTM levels (concentration/litre) measured in all patients.
V1 (BM harvest)
N = 26
V4 (6 wks)
N = 24 V4 versus V1
V5 (12 wks)
N = 24 V5 versus V1
V6 (24 wks)
N = 24 V6 versus V1
Mean± SEM
Median
Min–max
Mean± SEM
Median
Min–max
P value
Mean± SEM
Median
Min–max
P value
Mean± SEM
Median
Min–max
P value
BAP (μg/l)
20.11± 2.63 23.71± 3.24
0.035
23.55± 3.22
0.011
21.10± 1.99
0.41214.61 20.81 19.73 20.52
7.71–66.74 9.82–88.16 9.53–86.48 8.01–51.80
CTX (μg/l)
0.81± 0.10 0.62± 0.08
0.028
0.65± 0.10
0.014
0.62± 0.08
0.0730.75 0.51 0.50 0.56
0.14–2.50 0.28–2.15 0.20–2.11 0.13–1.84
int-OC (μg/l)
8.78± 0.56 7.28± 0.48
0.001
8.06± 0.62
0.036
8.58± 0.75
0.4219.26 7.85 8.18 8.47
3.82–12.96 3.51–10.91 3.80–13.86 3.22–14.24
N-mid OC (μg/l)
14.88± 1.91 13.13± 1.86
0.016
13.37± 2.12
0.290
14.42± 1.89
0.33013.76 10.62 11.38 11.81
1.35–47.08 4.51–42.94 1.91–51.30 2.28–34.67
OPG (pmol/l)
5.96± 0.75 5.81± 0.79
0.241
6.55± 0.87
0.056
5.48± 0.70
0.4654.51 5.12 5.44 4.37
1.63–16.11 1.53–19.48 1.45–18.90 1.62–14.55
PICP (μg/l)
121.26± 16.55 106.47± 15.33
0.016
113.44± 12.88
0.987
142.81± 18.48
0.57097.23 88.14 105.83 106.99
51.46–466.34 36.40–418.68 40.79–357.58 65.02–385.51
RANKL (pg/l)
0.19± 0.03 0.21± 0.06
0.455
0.14± 0.02
0.022
0.15± 0.03
0.1490.20 0.14 0.14 0.08
0.00–0.46 0.00–1.33 0.00–0.45 0.00–0.62
V1: visit 1; V4: visit 4; V5: visit 5; V6: visit 6; BAP: bone alkaline phosphatase; CTX: cross-linked C-telopeptide of type I collagen; int-OC: intact osteocalcin; N-
mid OC: N-terminal/midregion osteocalcin; OPG: osteoprotegerin; PICP: C-terminal propeptide of type I procollagen; RANKL: receptor activator of nuclear
factor kB ligand.
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early consolidation. A similar overall BTM trend was shared
by patients healed at 12 weeks and those with later consolida-
tion, but signiﬁcant changes were displayed already at 6
weeks by the “early” ones. Based on these ﬁndings, we can
suggest that the BTM kinetics is inﬂuenced by the healing
pace, but unfortunately, our hypothesis is not supported by
other studies dealing with a relation between BTM levels
and the timing of healing. However, it cannot be excluded
that the rate of callus formation and healing may be one of
the reasons of the high individual variability of BTM
observed in response to fracture, as remarked in a number
of papers [25, 32, 49].
In the single patient who did not reach the consolidation
at the end point, the variations of BAP and PICP, that is, the
bone formation markers, diﬀered consistently from the other
subjects. A similar picture is described by authors who
reviewed the role and potential of biochemical serum
markers as indicators of fracture healing disturbances [33,
34, 36, 50, 51]. In theory, the above molecules could reﬂect
a poor response to the regenerative treatment, but this cannot
be ascertained in our study because of the lack of failed cases.
Summarizing, the feasibility and eﬃcacy of the regenera-
tive treatment using a high amount of expanded MSC with
an osteoconductive material was the primary objective of this
phase I/IIa clinical trial, but some limitations emerge when
focusing on the role of BTM changes as “signals” of the
MSC regenerating ability. Taken together, our results prove
that BTM monitoring is practicable and suggests a possible
correlation with clinical results, but the real contribution of
the transplanted MSC/MBCP+ to the observed BTM changes
can be only hypothesized. In fact, BTM could vary also in the
absence of MSC implantation, but unfortunately, a control
group treated with a standard therapy without biological sup-
plementation was not included in the clinical protocol.
In addition, while the regenerative treatment was homo-
geneous for all patients, that is, same MSC dose, biomaterial
volume, and MSC/biomaterial ratio, the clinical heterogene-
ity, that is, the type of fracture, mobility, and ﬁxation devices,
could inﬂuence the BTM levels. Anyway, when considering
all variables, the number of patients recruited in our pilot
study was not large enough to obtain a statistical evidence.
5. Conclusion
Nonunions are among the leading indications for cell therapy
bone repair in everyday practice [30]. A nonsubjective assess-
ment of bone healing, possibly at an early stage, is eagerly
awaited by clinicians to predict treatment outcome, but cur-
rently, there is no reliable way to predict which patients will
beneﬁt from regenerative approaches. We evaluated a panel
of BTM that could reﬂect the healing rate, to be used as a sup-
plemental marker for monitoring or predicting consolida-
tion. Our data show that BTM (i) change after the MSC/
MBCP+ regenerative therapy, (ii) correlate to the imaging
results at certain follow-up time points, and (iii) diﬀer in
patients who had an “early consolidation.” Yet, despite the
remarkable diﬀerences in bone formation markers, the pre-
dictive value of BTM changes cannot be determined, since a
single failure was observed, that is, about 5% of the treated
cases. A recently approved trial with a large case series and
a control population treated with standard techniques will
allow to overcome the limits of the study and to assess if
BTM are useful for monitoring cell therapy eﬃcacy in
bone nonunions.
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Figure 4: The bars show the median and range (25th to 75th percentile) of BTM changes at visit 5 (a) and visit 6 (b). For each bone marker,
the variation at 12 weeks (visit 5) and 24 weeks (visit 6) has been related to the healing status (consolidation, incomplete, and failure) as
resulting from imaging at the same time points. BAP: bone alkaline phosphatase; CTX: cross-linked C-telopeptide of type I collagen; int-
OC: intact osteocalcin; N-mid OC: N-terminal/midregion osteocalcin; OPG: osteoprotegerin; PICP: C-terminal propeptide of type I
procollagen; RANKL: receptor activator of nuclear factor kB ligand; V1: baseline; V5: visit 5; V6: visit 6.
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Figure 5: The graphs show the median and range (25th to 75th percentile) of BTM changes from visit 1 (V1), chosen as the baseline value, to
visit 6 (V6). For each bone marker, the variation index recorded during the follow-up has been considered according to the ﬁnal
outcome. (a) BAP, bone alkaline phosphatase; (b) PICP, C-terminal propeptide of type I procollagen; (c) int-OC, intact osteocalcin;
(d) N-mid OC, N-terminal/midregion osteocalcin; (e) OPG, osteoprotegerin; (f) RANKL, receptor activator of nuclear factor kB
ligand; (g) CTX, cross-linked C-telopeptide of type I collagen.
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